0

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

Hengmiao Cheng, Sajiv K Nair, Brion W Murray, Chau Almaden, Simon Bailey, Sangita Baxi, Doug Behenna, Sujin Cho-Schultz, Deepak Dalvie, Dac M Dinh, Martin P Edwards, Jun Li Feng, Rose Ann Ferre, Ketan S Gajiwala, etc.

J Med Chem. 2016 Mar 10;59(5):2005-24.

PMID: 26756222

Abstract:

First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1428774451 PF-06459988 PF-06459988 1428774-45-1 Price
qrcode